依达拉奉联合降纤酶治疗脑梗死临床疗效观察

Therapeutic efficacy of edaravone-defibrase combination on acute brain infarction

目的观察依达拉奉联合降纤酶治疗急性脑梗死的临床疗效及安全性。方法48例患者随机分为2组,分别采用单用降纤酶及依达拉奉联合降纤酶治疗。以疗程14 d神经功能缺损评分及3个月时Barthel指数评分为标准观察疗效。结果两组病人疗程14 d神经功能缺损评分及3个月时Barthel指数差异有显著性意义。结论依达拉奉联合降纤酶治疗急性脑梗死安全有效,能显著改善患者的预后。

Objective To investigate the therapeutic efficacy and the safety of edaravone-defibrase combination on acute brain infarction. Methods Forty-eight patients with acute brain infarction were enrolled into the study and divided randomly into 2 groups. The patients in group A （n=25） were treated with the edaravone-defibrase combination, and ones in group B （n=23） were treated only with defibrase. The primary efficacy end points were functional status including favorable functional status （barthel index 1〉 95） and obvious dependent survival status （barthel index≤60） at 3 months. The secondary efficacy end points included chinese stroke neurological functional deficit scale at 14 d. Results There were a significantly greater proportion of favorable functional outcomes in group A than in group B at 3 months. The neurological functional deficits had more improvement in group A than in group B at 14 d. Conclusion The edaravone-defibrase combination is effective to improve the neurological function and the ability of daily living for acute cerebral infarction within 24 h of symptom onset.